Tuesday, 16 Jul 2019

You are here

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Noting studies that showed premature mortality among ESRD lupus nephritis patients, researchers set out to examine if these trends have continued. Using national registry data through 2014, they studied 20,974 patients with incident ESRD due to LN between January 1, 1995 and December 31, 2014 and examined outcomes in 5-year blocks (1995–1999, 2000–2004, 2005–2009, 2010–2014).

Between 1995 through 2014, the mortality rate per 100 patient- years declined steadily:

  • 1995–1999 - 11.1 (95% confidence interval [95% CI] 10.4–11.8)
  • 2010–2014 - 6.7 (95% CI 6.2–7.2) (P trend < 0.01).

Compared with 1995–1999, the adjusted mortality hazard ratios in 2010–2014 were lower for whites (0.68;0.58–0.78), African Americans (0.67; 0.57–0.78), and for Hispanics (0.51; 0.38–0.69).

Deaths from cardiovascular disease (CVD) and infection declined by 44% and 63%, over this same period (p< 0.01 for both).

It appears that improving care in this high- risk population has lead to a reduction in all- cause mortality among white, African American, and Hispanic patients, with reduced risk of death from CVD and infection. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Pregnancy Outcomes Improve in Lupus

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve. The large decline in in-hospital maternal mortality was greater for lupus pregnancies than for non-lupus pregnancies. Findings from a retrospective cohort study are published in Annals of Internal Medicine.

Blinded by the Use of Antimalarials in Lupus?

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Disparities in Lupus Survival

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively). Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.

Sjögren's Syndrome Differs in Minorities

Minority groups in the U.S. have differing rates of Sjögren's syndrome and exhibit distinct clinical patterns of the disease, a large cross-sectional study revealed. The percentage of American Indians in a SS cohort of 610 patients was much higher than expected, at 25.3%, whereas the percentage of African Americans was lower, at 3.1%. In addition, American Indians had higher levels of disease activity and more extraglandular manifestations, whereas African Americans had a symptom pattern associated with subsequent lymphoma development, researchers reported in Arthritis Care & Research.